<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Eli Lilly And Company — News on 6ix</title>
<link>https://6ix.com/company/eli-lilly-and-company</link>
<description>Latest news and press releases for Eli Lilly And Company on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/eli-lilly-and-company" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835924878dffbe2df102cef.webp</url>
<title>Eli Lilly And Company</title>
<link>https://6ix.com/company/eli-lilly-and-company</link>
</image>
<item>
<title>Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/lilly-to-acquire-kelonia-therapeutics-to-advance-in-vivo-car-t-cell-therapies</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/lilly-to-acquire-kelonia-therapeutics-to-advance-in-vivo-car-t-cell-therapies</guid>
<pubDate>Mon, 20 Apr 2026 13:00:00 GMT</pubDate>
<description>Eli Lilly and Company (NYSE: LLY) and Kelonia Therapeutics, Inc. ("Kelonia"), a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced a definitive agreement for Lilly to acquire Kelonia.</description>
</item>
<item>
<title>Lilly confirms date and conference call for first-quarter 2026 financial results announcement</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/lilly-confirms-date-and-conference-call-for-first-quarter-2026-financial-results-announcement</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/lilly-confirms-date-and-conference-call-for-first-quarter-2026-financial-results-announcement</guid>
<pubDate>Thu, 16 Apr 2026 14:00:00 GMT</pubDate>
<description>Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2026 financial results on April 30, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.</description>
</item>
<item>
<title>ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/achieve-4-the-longest-phase-3-study-of-lillys-foundayo-orforglipron-to-date-reaffirmed-its-cardiovascular-and-overall-safety-profile-as-well-as-consistent-improvements-across-key-measures-of-cardiometabolic-health</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/achieve-4-the-longest-phase-3-study-of-lillys-foundayo-orforglipron-to-date-reaffirmed-its-cardiovascular-and-overall-safety-profile-as-well-as-consistent-improvements-across-key-measures-of-cardiometabolic-health</guid>
<pubDate>Thu, 16 Apr 2026 10:45:00 GMT</pubDate>
<description>Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron), compared to insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk. ACHIEVE-4, the largest and longest study of Foundayo in type 2 diabetes to date, enrolled more than 2,700 participants across 15 countries. In the trial, Foundayo met the primary endpoint by demonstrating a no</description>
</item>
<item>
<title>Shed Adds Foundayo™ to Its Platform, Expanding Oral GLP-1 Access for Patients Nationwide</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/shed-adds-foundayotm-to-its-platform-expanding-oral-glp-1-access-for-patients-nationwide</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/shed-adds-foundayotm-to-its-platform-expanding-oral-glp-1-access-for-patients-nationwide</guid>
<pubDate>Wed, 15 Apr 2026 12:21:00 GMT</pubDate>
<description>Shed, a leading online health and wellness platform, today announced it is now offering Foundayo™ (orforglipron), Eli Lilly and Company's FDA-approved once-daily oral GLP-1 therapy for weight management. The addition gives Shed members a clinically proven, needle-free alternative to injectable GLP-1 treatments — one that requires no special meal timing and fits naturally into everyday life.</description>
</item>
<item>
<title>Vasa Therapeutics Partners with Lilly TuneLab to Power AI/ML-Driven CAMKII Inhibitor Platform</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/vasa-therapeutics-partners-with-lilly-tunelab-to-power-aiml-driven-camkii-inhibitor-platform</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/vasa-therapeutics-partners-with-lilly-tunelab-to-power-aiml-driven-camkii-inhibitor-platform</guid>
<pubDate>Tue, 14 Apr 2026 12:00:00 GMT</pubDate>
<description>Vasa Therapeutics ("Vasa"), a clinical stage biopharmaceutical company developing transformative therapies for cardiovascular, neuromuscular, and age-related disorders, today announced an agreement with Eli Lilly and Company ("Lilly") that enables the company to utilize Lilly TuneLab, an AI-enabled drug discovery platform that provides biotech companies access to drug discovery models trained on Lilly's proprietary data.</description>
</item>
<item>
<title>Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/lillys-jaypirca-pirtobrutinib-significantly-extended-progression-free-survival-when-added-to-a-venetoclax-time-limited-regimen-in-patients-with-previously-treated-cllsll</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/lillys-jaypirca-pirtobrutinib-significantly-extended-progression-free-survival-when-added-to-a-venetoclax-time-limited-regimen-in-patients-with-previously-treated-cllsll</guid>
<pubDate>Mon, 13 Apr 2026 10:45:00 GMT</pubDate>
<description>Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-322 trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Treatment in both study arms was administered for up to two years, after which patients do not take any CLL therapy unt</description>
</item>
<item>
<title>LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/lifemdr-now-offering-eli-lilly-and-companys-foundayotm-orforglipron-a-new-glp-1-pill-for-weight-management-1</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/lifemdr-now-offering-eli-lilly-and-companys-foundayotm-orforglipron-a-new-glp-1-pill-for-weight-management-1</guid>
<pubDate>Fri, 10 Apr 2026 12:15:00 GMT</pubDate>
<description>LifeMD expands its weight management program with the addition of Foundayo, offering eligible patients an oral alternative to injectable GLP-1 therapies through LillyDirect®NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that it is now offering Foundayo™ (orforglipron) to eligible patients through its weight management program. Foundayo, developed by Eli Lilly and Company, is a once daily oral treatmen</description>
</item>
<item>
<title>Weight Watchers Launches Eli Lilly and Company’s New Oral GLP-1 Foundayo® Available Through LillyDirect</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/weight-watchers-launches-eli-lilly-and-companys-new-oral-glp-1-foundayor-available-through-lillydirect</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/weight-watchers-launches-eli-lilly-and-companys-new-oral-glp-1-foundayor-available-through-lillydirect</guid>
<pubDate>Thu, 09 Apr 2026 13:00:00 GMT</pubDate>
<description>The addition of Foundayo® (orforglipron) gives Weight Watchers Med+ members a new FDA-approved oral GLP-1 option for weight lossNEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, announced that it is now offering access to Eli Lilly and Company’s newly FDA-approved oral GLP-1, Foundayo® (orforglipron) through its Med+ offering and affiliated medical groups. The addition gives members a new o</description>
</item>
<item>
<title>RO OFFERS ELI LILLY'S FOUNDAYO™, THE NEWEST GLP-1 INNOVATION</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/ro-offers-eli-lillys-foundayotm-the-newest-glp-1-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/ro-offers-eli-lillys-foundayotm-the-newest-glp-1-innovation</guid>
<pubDate>Thu, 09 Apr 2026 11:15:00 GMT</pubDate>
<description>Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo™ (orforglipron) – Eli Lilly Company's newest oral GLP-1 innovation – on the Ro platform, adding to Ro's already comprehensive formulary of FDA-approved GLP-1s. Foundayo™ is a once daily oral treatment for adults with obesity or overweight with weight-related medical problems.</description>
</item>
<item>
<title>Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/foundayotm-orforglipron-lillys-new-oral-glp-1-pill-for-weight-loss-now-available-in-the-us</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/foundayotm-orforglipron-lillys-new-oral-glp-1-pill-for-weight-loss-now-available-in-the-us</guid>
<pubDate>Thu, 09 Apr 2026 10:45:00 GMT</pubDate>
<description>Eli Lilly and Company (NYSE: LLY) today announced that Foundayo™ (orforglipron) is now available to adults with obesity or overweight with weight-related medical problems following the U.S. Food and Drug Administration (FDA) approval on April 1, 2026. When used alongside a reduced-calorie diet and increased physical activity, Foundayo helps individuals lose excess body weight and keep the weight off. Foundayo is a once-daily pill for weight loss that can be taken without food or water restrictio</description>
</item>
<item>
<title>RO LAUNCHES ELI LILLY'S KWIKPEN®, OFFERING PATIENTS A MORE CONVENIENT WAY TO TAKE ZEPBOUND®</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/ro-launches-eli-lillys-kwikpenr-offering-patients-a-more-convenient-way-to-take-zepboundr</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/ro-launches-eli-lillys-kwikpenr-offering-patients-a-more-convenient-way-to-take-zepboundr</guid>
<pubDate>Thu, 02 Apr 2026 17:01:00 GMT</pubDate>
<description>Ro, the leading direct-to-patient healthcare company, today announced that it is working with Eli Lilly to launch the recently FDA-approved Zepbound® (tirzepatide) KwikPen® nationwide on its platform. The prefilled, multi-dose pen offers a convenient way for patients to take the most effective GLP-1 medication available. Patients can visit Ro.co to access the KwikPen along with ongoing high-quality clinical care, including 24/7 messaging, 1-1 coaching, educational content, weight tracking and do</description>
</item>
<item>
<title>FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/fda-approves-lillys-foundayotm-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions-2</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/fda-approves-lillys-foundayotm-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions-2</guid>
<pubDate>Wed, 01 Apr 2026 15:30:00 GMT</pubDate>
<description>Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems. When used alongside a reduced-calorie diet and increased physical activity, Foundayo helps individuals lose excess body weight and keep the weight off. Foundayo will be available via LillyDirect®, with prescriptions accepted immediately and shipping beginning April 6, followed shortly after by</description>
</item>
<item>
<title>Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/lilly-to-acquire-centessa-pharmaceuticals-to-advance-treatments-for-sleep-wake-disorders</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/lilly-to-acquire-centessa-pharmaceuticals-to-advance-treatments-for-sleep-wake-disorders</guid>
<pubDate>Tue, 31 Mar 2026 10:45:00 GMT</pubDate>
<description>Eli Lilly and Company (NYSE: LLY) and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, today announced a definitive agreement for Lilly to acquire Centessa.</description>
</item>
<item>
<title>Insilico Medicine Announces Global R&D Collaboration with Lilly</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/insilico-medicine-announces-global-randd-collaboration-with-lilly</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/insilico-medicine-announces-global-randd-collaboration-with-lilly</guid>
<pubDate>Mon, 30 Mar 2026 00:30:00 GMT</pubDate>
<description>Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI) and automation, today announced a drug discovery collaboration with Eli Lilly and Company ("Lilly") that uses Insilico's AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas.</description>
</item>
<item>
<title>Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/phase-3b-data-presented-at-aad-annual-meeting-show-lillys-taltz-ixekizumab-plus-zepbound-tirzepatide-delivered-superior-efficacy-for-adults-with-psoriatic-arthritis-and-obesity</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/phase-3b-data-presented-at-aad-annual-meeting-show-lillys-taltz-ixekizumab-plus-zepbound-tirzepatide-delivered-superior-efficacy-for-adults-with-psoriatic-arthritis-and-obesity</guid>
<pubDate>Sat, 28 Mar 2026 19:15:00 GMT</pubDate>
<description>Eli Lilly and Company (NYSE: LLY) today announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with active psoriatic arthritis (PsA) and obesity or overweight with at least one additional weight-related comorbid condition. These results were presented in a late-breaking presentation at the 2026 American Academy of Dermatology (AAD) Annual Meeting and simu</description>
</item>
<item>
<title>Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/lillys-ebglyss-lebrikizumab-lbkz-delivered-up-to-four-years-of-durable-disease-control-for-patients-with-moderate-to-severe-atopic-dermatitis</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/lillys-ebglyss-lebrikizumab-lbkz-delivered-up-to-four-years-of-durable-disease-control-for-patients-with-moderate-to-severe-atopic-dermatitis</guid>
<pubDate>Fri, 27 Mar 2026 13:00:00 GMT</pubDate>
<description>New long-term data show Eli Lilly and Company's (NYSE: LLY) EBGLYSS (lebrikizumab-lbkz) delivered durable skin clearance and relief from persistent itch for up to four years for patients with moderate-to-severe atopic dermatitis (eczema) in an open-label extension study offering once-monthly maintenance injection. Interim findings from the first year of the ADlong Phase 3b study will be presented at the American Academy of Dermatology (AAD) Annual Meeting, taking place March 27-31 in Denver.1</description>
</item>
<item>
<title>Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/lillys-triple-agonist-retatrutide-demonstrated-significant-reductions-in-a1c-and-weight-in-first-phase-3-trial-for-treatment-of-type-2-diabetes</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/lillys-triple-agonist-retatrutide-demonstrated-significant-reductions-in-a1c-and-weight-in-first-phase-3-trial-for-treatment-of-type-2-diabetes</guid>
<pubDate>Thu, 19 Mar 2026 10:45:00 GMT</pubDate>
<description>Eli Lilly and Company (NYSE: LLY) today announced positive topline results from TRANSCEND-T2D-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, as an adjunct to diet and exercise. The trial enrolled adults diagnosed with type 2 diabetes with inadequate glycemic control with diet and exercise alone, and a mean duration of diabetes of 2.5 years. In the study, retatrutide met the</description>
</item>
<item>
<title>Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/lillys-ebglyss-lebrikizumab-lbkz-is-the-first-and-only-selective-il-13-inhibitor-to-deliver-positive-phase-3-outcomes-in-patients-aged-six-months-to-18-years-with-moderate-to-severe-atopic-dermatitis</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/lillys-ebglyss-lebrikizumab-lbkz-is-the-first-and-only-selective-il-13-inhibitor-to-deliver-positive-phase-3-outcomes-in-patients-aged-six-months-to-18-years-with-moderate-to-severe-atopic-dermatitis</guid>
<pubDate>Mon, 16 Mar 2026 10:45:00 GMT</pubDate>
<description>Eli Lilly and Company (NYSE: LLY) today announced positive, topline results from the Phase 3 ADorable-1 trial evaluating the safety and efficacy of EBGLYSS (lebrikizumab-lbkz) in pediatric patients with moderate-to-severe atopic dermatitis. EBGLYSS met the primary and key secondary endpoints at Week 16, improving disease severity while delivering skin clearance and relief from persistent itch. Atopic dermatitis is more common in children than adults, affecting 9.6 million children in the U.S., o</description>
</item>
<item>
<title>Samsung Biologics Announces Collaboration with Lilly to Establish New Gateway Labs Site in Korea</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/samsung-biologics-announces-collaboration-with-lilly-to-establish-new-gateway-labs-site-in-korea</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/samsung-biologics-announces-collaboration-with-lilly-to-establish-new-gateway-labs-site-in-korea</guid>
<pubDate>Tue, 10 Mar 2026 11:00:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced a collaboration agreement with Eli Lilly and Company (Lilly) to establish a Lilly Gateway Labs (LGL) site in Korea.</description>
</item>
<item>
<title>15 Top Press Releases from February</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/15-top-press-releases-from-february</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/15-top-press-releases-from-february</guid>
<pubDate>Fri, 06 Mar 2026 11:02:00 GMT</pubDate>
<description>With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the month's most newsworthy and popular releases, here's a recap of some major stories from the last month that shouldn't be missed.</description>
</item>
</channel>
</rss>